Company intelligence / Profile preview
EmpowerPharm Inc.
Burlington, Ontario, Canadaempowerpharm.ca ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
EmpowerPharm has completed promising Phase 2 clinical trials of its proprietary high-bioavailability CBD oral formulation for social anxiety disorder. The company demonstrated an effective dose of CBD at 300 mg and will use a new high-bioavailability capsule formulation in upcoming Phase 3 studies. The company’s SNEDDS technology improves absorption and therapeutic effect. Regulatory submissions are planned in Canada, the U.S., and internationally with commercial launch preparations underway.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules (cannabinoid-based, specifically pharmaceutical-grade cannabidiol/CBD)Proprietary oral solid dose formulations (tablets, capsules)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not specified in public sources.
Beyond the preview
Go deeper on EmpowerPharm Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EmpowerPharm Inc..